ES2287500T3 - Composicion quimica igf para el tratamiento y prevencion de enfermedades neurodegenerativas. - Google Patents

Composicion quimica igf para el tratamiento y prevencion de enfermedades neurodegenerativas. Download PDF

Info

Publication number
ES2287500T3
ES2287500T3 ES03744388T ES03744388T ES2287500T3 ES 2287500 T3 ES2287500 T3 ES 2287500T3 ES 03744388 T ES03744388 T ES 03744388T ES 03744388 T ES03744388 T ES 03744388T ES 2287500 T3 ES2287500 T3 ES 2287500T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
neurodegenerative diseases
igf
chemical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03744388T
Other languages
English (en)
Inventor
Lopez C Lopez
Diaz E M Carro
Alem N I Torres
Duran J J Torrado
Duran S Torrado
Celia Carrascosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Complutense de Madrid
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Complutense de Madrid filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Application granted granted Critical
Publication of ES2287500T3 publication Critical patent/ES2287500T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a nuevas composiciones terapéuticas de administración lenta de IGF-I, a un procedimiento de preparación y obtención de las mismas y a su empleo para la elaboración de medicamentos para el tratamiento y prevención de enfermedades neurodegenerativas como, entre otras, la enfermedad de Alzheimer o la ataxia cerebelar.Estas composiciones se corresponden con microesferas de tamaño menor de 5 micrometros, entre otras características, y con cápsulas de implantación subcutánea.
ES03744388T 2002-02-28 2003-02-21 Composicion quimica igf para el tratamiento y prevencion de enfermedades neurodegenerativas. Expired - Lifetime ES2287500T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200491A ES2207387B1 (es) 2002-02-28 2002-02-28 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
PCT/ES2003/000087 WO2003077940A1 (es) 2002-02-28 2003-02-21 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas

Publications (1)

Publication Number Publication Date
ES2287500T3 true ES2287500T3 (es) 2007-12-16

Family

ID=27838351

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200200491A Expired - Fee Related ES2207387B1 (es) 2002-02-28 2002-02-28 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
ES03744388T Expired - Lifetime ES2287500T3 (es) 2002-02-28 2003-02-21 Composicion quimica igf para el tratamiento y prevencion de enfermedades neurodegenerativas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200200491A Expired - Fee Related ES2207387B1 (es) 2002-02-28 2002-02-28 Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.

Country Status (13)

Country Link
US (1) US20050208126A1 (es)
EP (1) EP1488801B1 (es)
JP (1) JP2005529083A (es)
AT (1) ATE361094T1 (es)
AU (1) AU2003209777B2 (es)
CA (1) CA2477593C (es)
DE (1) DE60313593T2 (es)
DK (1) DK1488801T3 (es)
ES (2) ES2207387B1 (es)
MX (1) MXPA04008402A (es)
PL (1) PL373382A1 (es)
PT (1) PT1488801E (es)
WO (1) WO2003077940A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587601C (en) * 2004-12-03 2017-11-07 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2008111520A1 (ja) * 2007-03-09 2008-09-18 Nagasaki University 寿命延長関連遺伝子およびその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5705197A (en) * 1994-05-16 1998-01-06 The United States Of America As Represented By The Secretary Of The Army Extraction process for producing PLGA microspheres
US5888551A (en) * 1995-12-11 1999-03-30 University Of Miami Hair growth stimulating composition
ES2158611T3 (es) * 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
US5861149A (en) * 1997-06-04 1999-01-19 Polyheal Ltd. Methods for wound treatment
AU1384199A (en) * 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants

Also Published As

Publication number Publication date
DE60313593D1 (de) 2007-06-14
CA2477593A1 (en) 2003-09-25
WO2003077940A1 (es) 2003-09-25
PL373382A1 (en) 2005-08-22
CA2477593C (en) 2012-05-15
ES2207387A1 (es) 2004-05-16
EP1488801B1 (en) 2007-05-02
JP2005529083A (ja) 2005-09-29
DK1488801T3 (da) 2007-09-10
US20050208126A1 (en) 2005-09-22
AU2003209777B2 (en) 2008-01-10
ES2207387B1 (es) 2005-07-16
AU2003209777A1 (en) 2003-09-29
MXPA04008402A (es) 2005-07-27
EP1488801A1 (en) 2004-12-22
ATE361094T1 (de) 2007-05-15
PT1488801E (pt) 2007-08-14
DE60313593T2 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
MXPA06011194A (es) Tiadiazolidinonas como inhibidores de gsk-3.
MY129422A (en) Medicinal compounds
TNSN04165A1 (en) Substituted hydroxyethylamines
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
CA2427227A1 (en) Lactam compound
TW200745135A (en) Therapeutic agents
SE0104340D0 (sv) New compounds
TW200502221A (en) Novel lactams and uses thereof
IL175762A0 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
TW200635589A (en) Therapeutic agents
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
SE0104331D0 (sv) Novel compounds
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
TW200501963A (en) Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
ES2287500T3 (es) Composicion quimica igf para el tratamiento y prevencion de enfermedades neurodegenerativas.
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BR0312453A (pt) Implante para o transporte e a liberação de agentes farmacologicamente ativos e processo para a produção do mesmo
HK1075894A1 (en) Prucalopride-n-oxide
TW200504036A (en) Novel lactams and uses thereof
MX2023005935A (es) Compuestos aromaticos que contienen boro y analogos de insulina.
RU2003126176A (ru) Кислотно-аддитивные соли тербинафина и яблочной кислоты